News Coverage & Scientific Studies
There are several new studies, stories, and reports offering insights into the psychedelic research field and their medical benefits.
News
-
Legal Use of Hallucinogenic Mushrooms Begins in Oregon
New York Times | January 2023Australia The First Nation To Approve The Legal Use Of MDMA And Psilocybin
Forbes | February 2023Inside Synthesis Institute’s Implosion
Psychedelic Alpha | March 2023FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs
FDA News Release | June 2023A New Era of Psychedelics in Oregon
New York Times | October 2023FDA to Review MDMA-Assisted Therapy, a Milestone for Psychedelics
Washington Post | December 2023 -
A Psychedelic Renaissance at the VA.
New York Times | June 2022Lawmakers Announce Bipartisan Psychedelic Caucus
Psychedelic Spotlight | November 2022 -
Veterans Have Become Unlikely Lobbyists in Push to Legalize Psychedelic Drugs
New York Times | November 2021
New Research Shows How Psychedelic Drug Can Help People With PTSD
Today | November 2021
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same
New York Times | May 2021
A Psychedelic Drug Passes a Big Test for PTSD Treatment
New York Times | May 2021
How ecstasy and psilocybin are shaking up psychiatry
Nature.com | January 2021 -
Rigorous Study Backs A Psychedelic Treatment For Major Depression
NPR | November 2020
The case for funding psychedelics to treat mental health
Vox | October 2020
Turn On, Tune In, Get Well
New Yorker | October 2020
Who Will Benefit From Psychedelic Medicine?
Washington Post | September 2020
These Four Former Pro Athletes Are Using Psychedelics To Heal Their Brain Injuries
Forbes | November 2020
Psychedelic Pioneer Rick Doblin On FDA Trials Of MDMA: Most Important Reality Check Of MAPS’ 34-Year History
Forbes | May 2020
MDMA Therapy Training for Communities of Color
MAPS | Spring 2020
Couple says psychedelic drugs made them better parents
The Today Show | March 2020
Single dose of psychedelic drug eased cancer patients' anxiety, depression for years
NBC | January 2020 -
How magic mushrooms can help smokers kick the habit
NPR | October 2019
MAPS Receives $4,140,000 Grant from Psychedelic Science Funders Collaborative (PSFC)
MAPS Newsletter | May 2019
The extraordinary therapeutic potential of psychedelic drugs, explained
Vox | January 2019 -
Psychedelic Retreats And The Future Of Mental Health: A Review
Forbes | October 2018
Psychedelic Mushrooms Are Closer to Medicinal Use (It’s Not Just Your Imagination)
New York Times | October 2018
How MDMA is being used to treat PTSD (video, 7 minutes)
The Economist | October 2018
Ecstasy as a Remedy for PTSD? You Probably Have Some Questions.
New York Times | May 2018
Can a Party Drug Treat PTSD?
“Health Talk” on Fox News | May 2018
"Running Away or Righting Away: Is Psilocybin a Viable Psychiatric Treatment?"
Charles Raison MD and Michael Bogenschutz MD discuss the history and potential of psilocybin research | MD Magazine | Feb 2018 -
Ecstasy could be ‘breakthrough’ therapy for soldiers, others suffering from PTSD
Washington Post | Aug 2017
The Promise of Ecstasy for PTSD
New York Times | Nov 2017
Will Psychedelic Therapy Transform Mental Health Care?
NBC | Sept 2017
"Decoding the Tripping Brain"
The Scientist | Sept 2017
All clear for the decisive trial of ecstasy in PTSD patients
Science Magazine | Aug 2017
"Why psychedelic drugs are having a medical renaissance"
PBS Newshour | Jan 2017 -
Just One Dose of This Psychedelic Drug Can Ease Anxiety
Time | Dec 2016 -
-
Hallucinogens Have Doctors Tuning In Again
New York Times | 2010
Medical Reports & Scientific Studies
-
The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns
The American Journal of Geriatric Psychiatry | January 2023Considerations in assessing the abuse potential of psychedelics during drug development
Neuropharmacology | February 2023The therapeutic potential of psychedelics: the European regulatory perspective
The Lancet | March 2023Psychedelic Medicine's Future Depends on Proactive Development of a Robust Medical Billing and Coding Strategy
Psychedelic Medicine | March 2023Human brain effects of DMT assessed via EEG-fMRI
PNAS | March 2023Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics
Journal of Psychoactive Drugs | April 2023 -
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
JAMA Psychiatry | August 2022Psychedelic medicine
Nature Outlook | September 2022Notice of Information on NIMH's Considerations for Research Involving Psychedelics and Related Compounds
NIH | November 2022Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care
Cambridge Quarterly of Healthcare Ethics | 2022 -
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Nature Medicine | May 2021 -
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD
PLOS One | October 2020Psychedelic Psychiatry’s Brave New World
Cell | April 2020
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Frontiers in Psychology | February 2020
Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame
Journal of Contextual Behavioral Science | January 2020 -
-
Psychiatry might need some psychedelic therapy
International Review of Psychiatry | December 2018
Effects of psilocybin therapy on personality structure
Acta Psychiatrica Scandinavica | June 2018
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Neuropharmacology | May 2018
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
The Lancet Psychiatry | May 2018 -
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Scientific Reports | Oct. 2017 -
Hallucinogenic drug found in 'magic mushrooms' eases depression, anxiety in people with life-threatening cancer
Johns Hopkins University | Dec. 2016
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
New York University, Journal of Psychopharmacology | Dec. 2016
Single Dose of Hallucinogenic Drug Psilocybin Relieves Anxiety & Depression in Patients with Advanced Cancer
NYU Langone Health | Dec. 2016
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Sage Journals | Nov. 2016
Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy
Journal of Psychopharmacology | Apr. 2016
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
The Lancet Psychiatry | Apr 2016
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
MAPS, Progress in Neuropsychopharmacology and Biological Psychiatry | Jan. 2016 -
-
-
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Johns Hopkins University | Jan. 2006